Novo Nordisk A/S, (NVO) Fair Value & Analysis
Healthcare · US · Market cap $191B
Novo Nordisk A/S,
NVO · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from $64.05 to $63.62 (−0.7%) since Jun 23, 2026. Share price +5.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $34.39 – $67.65 · fair‑value band $39.34 – $104.52 · the $47.42 price screens below the $63.62 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Novo Nordisk A/S, (NVO) currently trades at $47.42, while our model-based Fair Value estimate is $63.62 — implying the stock looks roughly 34.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Novo Nordisk A/S, generated revenue of $328B at a net margin of 37.2%. Revenue grew 24.0% year over year. It earns a return on equity of 71.4%. Net debt stands at $104B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquarter…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Novo Nordisk A/S, reported revenue of $309B in FY2025 versus $141B in FY2021, a compound +21.7%/yr. Reported net income was $102B in FY2025, compounding +21.0%/yr from FY2021.
Open the full interactive analysis →
Recent news
- Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?
- Here's Why Shares of Eli Lilly Hit an All-Time High on Friday
- Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
- Novo Nordisk A/S - share repurchase programme
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $224.95 | $129.90 | -42% |
| Roche Holding ROGN | 7,050 MXN | 316.37 MXN | -96% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| AstraZeneca PLC A1ZN34 | R$159.89 | R$87.02 | -46% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Novo Nordisk A/S, (NVO) undervalued?
What is the fair value of NVO?
What is the quality score of NVO?
What is the revenue of Novo Nordisk A/S, (NVO)?
What is the net profit margin of NVO?
Does Novo Nordisk A/S, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.